Fatty Liver Tracked With Kidney Risk in Two 2026 Cohorts

Two large Korean studies published in 2026 connect the liver to a partner organ most fatty-liver readers never hear about: the kidney. The first, in Gut and Liver (volume 20), followed 70,361 adults without baseline chronic kidney disease through 475,835 person-years of health checkups, and asked a simple question: do people with steatotic liver disease develop CKD more often?

The answer ran in a clean gradient. Over a mean of 6.8 years, 2,723 participants developed CKD, and steatotic liver disease carried a 17 percent higher risk (aHR 1.17), rising to 25 percent for MASLD specifically (aHR 1.25) and 32 percent for the alcohol-plus-metabolic category, with the risk climbing further as fibrosis severity advanced inside each classification.

The second study flips the direction of the question. Published in Kidney International Reports (May 2026), it took 187,881 people who already had CKD from Korea’s national screening database and followed them a median of 9.28 years, during which 7,497 progressed to kidney failure, and MASLD raised that risk by 15 percent (HR 1.146) compared with CKD patients without fatty liver.

The female signal is the detail that repeats across the subgroups. The kidney-failure association was strongest in women (HR 1.30), in older patients, in those without hypertension or albuminuria, and in nonsmokers, a pattern the authors read as risk stratification, the baseline-risk groups are where the fatty-liver signal shows most clearly, and the pattern echoes the female-specific signals in this month’s food-insecurity and frailty work.

A third 2026 paper explains why causality is contested. A meta-analysis and Mendelian randomization study in Nutrition & Diabetes pooled 34 studies and 3,783,136 participants, confirmed that MASLD tracks with CKD (HR 1.34), but found no causal effect of the fatty liver itself on kidney risk in the genetics, while genetically predicted BMI, blood pressure, triglycerides, and diabetes did carry causal weight.

The genetics finding is the one to read twice, because it changes where the reader acts. If the metabolic comorbidities carry the causal weight, then the interventions this site exists for, the friendly plate, the weight trend, the movement, the blood-pressure discipline, are acting on the kidney through the same channels as on the liver, and the organs are one project.

The severity gradient inside the cohort study reinforces it. CKD risk climbed with fibrosis stage within every disease classification, which means the fibrosis numbers this site keeps pointing at, FIB-4, stiffness, are kidney numbers too, and the reader managing liver fibrosis is managing a two-organ risk with one set of habits.

The honest limits are the usual cohort ones plus one Korean-specific caveat. Ultrasound-based steatosis classification can misclassify, eGFR-based CKD definitions miss albuminuric disease, and the Korean screening population differs in obesity prevalence from US populations, so the magnitudes may not travel even if the direction does, which the authors of both studies acknowledge.

The albuminuria detail is worth a sentence for accuracy. The kidney-failure association was strongest in the nonalbuminuria subgroup, which is counterintuitive until the risk-stratification logic lands: patients with albuminuria were already so high-risk that the fatty liver added little on top, while in lower-risk CKD the MASLD signal had room to show itself.

For a reader with MASLD and healthy kidneys, the practical translation is reassurance plus discipline. These are observational gradients, not sentences, and the two-organ strategy is the same one this site rates food by: the beans, whole grains, and vegetables that lower liver fat also feed the blood-pressure and glucose control the kidneys depend on.

For a reader with both conditions, the studies argue for a merged conversation. Nephrology and hepatology questions overlap more than clinic schedules assume, the FIB-4 score and the eGFR come from the same blood draw, and a reader who brings both numbers to one visit gets a care plan that treats the two organs as the system they are.

None of this replaces the clinician. Kidney disease management involves medication dosing that changes with renal function, and magnesium, potassium, and protein recommendations in CKD differ sharply from the general liver-friendly plate, which makes professional supervision the non-negotiable layer for any reader with established CKD.

For a reader, the takeaway is a second organ with the same lever: fatty liver tracked with new kidney disease and faster kidney failure, the genetics point at the shared metabolic load, and the plate this site rates is the intervention that pulls on that load for both organs at once.

The sodium footnote belongs last because it belongs to both organs at once. The pickles, processed meats, and canned soups that carry sodium flags in this database are the same items a nephrologist circles, and the reader who adopted the low-sodium discipline for the liver’s sake has been doing kidney work all along, which is the kind of overlap that makes the friendly plate feel less like a diet and more like a systems upgrade.

The takeaway sentence for the week is that the extrahepatic map keeps filling in, cardiovascular disease first, then bones, brain, and now kidneys with cohort-scale numbers, and every new organ on the map is an organ the same friendly plate serves, which is why the food-first position keeps surviving every new dataset thrown at it.

The hydration-and-herbals aside belongs here because readers managing two organs often reach for the supplement aisle, and the CKD context changes the math on several of this site’s friendly foods. Herbal teas, high-potassium juices, and protein-heavy patterns are liver-friendly in isolation and nephrology-managed in combination, which is the cleanest example on the site of a rating that must be read through the reader’s whole diagnosis rather than one label.